Molecular Formula | C17H23N3O2 |
Molar Mass | 301.38 |
Density | 1.166±0.06 g/cm3(Predicted) |
Boling Point | 584.0±50.0 °C(Predicted) |
Solubility | DMSO: >10mg/mL, clear |
Appearance | white powder |
pKa | 14.39±0.10(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months. |
In vitro study | (-)-Indolactam V is a PKC activator, with K i s of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and has antitumor activity. (-)-Indolactam V shows K d s of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), respectively. (-)-Indolactam V (20 nM-5 μM) dose-dependently affects multiple hESC lines, such as HUES 2, 4 and 8. (-)-Indolactam V also increases the mRNA levels of Pdx1, HNF6, PTF1A, SOX9, HB9 and PROX1. In addition, (-)-Indolactam V (300 nM) functions in both mouse and human cells and confirms that some signals for pancreatic development. |
WGK Germany | 3 |
RTECS | UY8547000 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.318 ml | 16.59 ml | 33.181 ml |
5 mM | 0.664 ml | 3.318 ml | 6.636 ml |
10 mM | 0.332 ml | 1.659 ml | 3.318 ml |
5 mM | 0.066 ml | 0.332 ml | 0.664 ml |
biological activity | (-)-Indolactam V is an activator of PKC, and it is important for p-crd2 (PKC N instead of peptide), the Ki values of γ-CRD2 (pkcγ instead of peptide) are 3.36 nM and 1.03 μm, and the Kd values for PKC C1A and C1B domains are 5.5 nM (δ-c1b), respectively, 7.7 nM (δ-C1B),8.3 nM (δ-C1B),18.9 nM (β-C1A-long),20.8 nM (α-C1A-long),137 nM (β-C1B),138 nM (γ-C1A) and 213 nM (γ-C1B), with anti-tumor activity. |